Shots:

• The company reported results from the P-I/IIa study evaluating EVX-02 in combination with a checkpoint inhibitor and targeting cancer mutations neoantigens in patients with resected melanoma. The results from the P-I study are expected in Q2’23
• The interim safety and immunogenicity data from the first eight patients showed that EVX-02 induced CD4+ and CD8+ specific T-cell responses in all patients & provides proof of mechanism for DNA-delivery technology & EVX-02-DNA offers immune reactions to its encoded neoantigen peptides
• The therapy was well tolerated & mild AEs observed, T-cell responses were robust and long-lasting

Ref: Globenewswire | Image: Evaxion